- Home
- MDWD vs BRKH Comparison
MDWD vs BRKH Comparison
Compare MDWD & BRKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- BRKH
- Stock Information
- Founded
- MDWD 2000
- BRKH 2021
- Country
- MDWD Israel
- BRKH United States
- Employees
- MDWD N/A
- BRKH N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- BRKH Blank Checks
- Sector
- MDWD Health Care
- BRKH Finance
- Exchange
- MDWD Nasdaq
- BRKH Nasdaq
- Market Cap
- MDWD 198.4M
- BRKH 170.5M
- IPO Year
- MDWD 2014
- BRKH 2021
- Fundamental
- Price
- MDWD $16.60
- BRKH $11.28
- Analyst Decision
- MDWD Strong Buy
- BRKH
- Analyst Count
- MDWD 1
- BRKH 0
- Target Price
- MDWD $28.00
- BRKH N/A
- AVG Volume (30 Days)
- MDWD 72.0K
- BRKH 20.9K
- Earning Date
- MDWD 08-14-2024
- BRKH 01-01-0001
- Dividend Yield
- MDWD N/A
- BRKH N/A
- EPS Growth
- MDWD N/A
- BRKH N/A
- EPS
- MDWD N/A
- BRKH N/A
- Revenue
- MDWD $20,141,000.00
- BRKH N/A
- Revenue This Year
- MDWD $30.16
- BRKH N/A
- Revenue Next Year
- MDWD $18.44
- BRKH N/A
- P/E Ratio
- MDWD N/A
- BRKH N/A
- Revenue Growth
- MDWD N/A
- BRKH N/A
- 52 Week Low
- MDWD $7.10
- BRKH $10.47
- 52 Week High
- MDWD $24.00
- BRKH $11.28
- Technical
- Relative Strength Index (RSI)
- MDWD 40.31
- BRKH 75.39
- Support Level
- MDWD $16.85
- BRKH $11.12
- Resistance Level
- MDWD $20.55
- BRKH $11.24
- Average True Range (ATR)
- MDWD 1.00
- BRKH 0.01
- MACD
- MDWD -0.24
- BRKH 0.01
- Stochastic Oscillator
- MDWD 6.62
- BRKH 100.00
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About BRKH BurTech Acquisition Corp.
BurTech Acquisition Corp is a blank check company.